MICHAEL LEWIS to Biomarkers, Tumor
This is a "connection" page, showing publications MICHAEL LEWIS has written about Biomarkers, Tumor.
Connection Strength
0.100
-
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
Score: 0.054
-
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight. 2020 08 06; 5(15).
Score: 0.012
-
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220.
Score: 0.011
-
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
Score: 0.010
-
A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene. 2014 Jun 12; 33(24):3099-108.
Score: 0.008
-
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
Score: 0.005